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1. INTRODUCTION {#jmd212051-sec-0001}
===============

Ketone bodies, generated from fatty acids, play an important role as an alternative energy source when glucose supply is low.[1](#jmd212051-bib-0001){ref-type="ref"}, [2](#jmd212051-bib-0002){ref-type="ref"} Mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA (HMG‐CoA) synthase (EC2.3.3.10) is a key enzyme that mediates the rate‐limiting step of ketone body synthesis, catalyzing the condensation reaction between the acetyl‐CoA and acetoacetyl‐CoA to HMG‐CoA.[3](#jmd212051-bib-0003){ref-type="ref"}

Mitochondrial HMG‐CoA synthase deficiency (mHS deficiency; OMIM No. 605991) is a rare autosomal recessive inborn error of ketogenesis caused by mutations in the *HMGCS2* (3‐hydroxy‐3‐methylglutaryl‐CoA synthase‐2) gene, located on chromosome 1p12‐13, which consists of 10 exons.[4](#jmd212051-bib-0004){ref-type="ref"}, [5](#jmd212051-bib-0005){ref-type="ref"}, [6](#jmd212051-bib-0006){ref-type="ref"}

mHS deficiency was first described in 1997.[7](#jmd212051-bib-0007){ref-type="ref"} To date, more than 20 cases have been reported.[8](#jmd212051-bib-0008){ref-type="ref"}, [9](#jmd212051-bib-0009){ref-type="ref"}, [10](#jmd212051-bib-0010){ref-type="ref"}, [11](#jmd212051-bib-0011){ref-type="ref"}, [12](#jmd212051-bib-0012){ref-type="ref"}, [13](#jmd212051-bib-0013){ref-type="ref"}, [14](#jmd212051-bib-0014){ref-type="ref"}, [15](#jmd212051-bib-0015){ref-type="ref"}, [16](#jmd212051-bib-0016){ref-type="ref"}, [17](#jmd212051-bib-0017){ref-type="ref"} Most patients presented with hypoglycemia and hepatomegaly during acute infection and prolonged fasting and showed an absence of clinical symptoms in the intermittent phase. Non‐(hypo)‐ketotic hypoglycemia with high free fatty acids (FFA) is the predominant laboratory finding.[18](#jmd212051-bib-0018){ref-type="ref"} Clinical presentations are similar to fatty acid β‐oxidation defects, however, no specific acylcarnitine profile is found in mHS deficiency. Although 4‐hydroxy‐6‐methyl‐2‐pyrone (4HMP) in urine was recently reported as a possible useful specific marker,[13](#jmd212051-bib-0013){ref-type="ref"} diagnosis of mHS deficiency is still challenging owing to poor biochemical markers. Therefore, diagnosis of mHS deficiency is based on genetic analysis.

Here, we report the case of a Japanese boy with mHS deficiency who did not present with hypoglycemia in the acute phase. We describe the detailed clinical course and characteristics of the present case together with previously reported cases.

2. CASE PRESENTATION {#jmd212051-sec-0002}
====================

A 12‐month‐old Japanese boy born to nonconsanguineous parents was a second child with a healthy elder sister. He had grown and developed normally. No abnormalities were detected in a newborn screenings using tandem mass spectrometry. He presented with a fever, upper respiratory symptoms, and loss of oral intake. After 7 days of febrile illness, he was admitted to the hospital because of polypnea and cyanosis. Influenza A was detected in a rapid test. Laboratory investigation (Supporting Information Table [S1](#jmd212051-supitem-0003){ref-type="supplementary-material"}) revealed mild hyperammonemia (173 μg/dL), elevated aspartate aminotransferase (AST; 461 IU/L) and alanine aminotransferase (ALT; 142 IU/L) levels and severe metabolic acidosis (pH 6.985, pCO~2~ 13.8 mmHg, HCO~3~ 3.2 mmol/L, BE −26.5 mmol/L; and anion gap, 30.5 mmol/L). The creatine kinase, lactic acid, and pyruvic acid levels were normal. Hypoglycemia was not detected (9.39 mmol/L) before glucose infusion was started. While the level of FFA was elevated (1.31 mmol/L), that of acetoacetic acid did not increase (0.04 mmol/L) and that of 3‐hydroxybutyrate was only mildly elevated (0.154 mmol/L).

Physical examination revealed marked hepatomegaly. Abdominal computed tomography (CT) revealed severe fatty liver and hepatomegaly without splenomegaly (Figure [1](#jmd212051-fig-0001){ref-type="fig"}).

![The clinical course and laboratory data. The ratio of FFA to total ketone bodies (6.75; normal range, 0.3‐2.5) was high at onset and even much higher in the intermittent phase. The AST and ALT values were extremely elevated at onset and then decreased dramatically. Around 3 months after the first crisis, the values spiked due to enteritis. In 7 months after the onset, the AST and ALT values finally normalized. The CT scan performed on day 2 revealed a prominent, enlarged and fatty liver. On day 11, these findings had improved somewhat. In month 3, the liver had enlarged again due to enteritis. In 13 months, the fatty liver had mostly disappeared, but the hepatomegaly still remained. \**L*/*S* ratio: the ratio of the CT value in the liver to that in the spleen. An *L*/*S* ratio of \<1.0 mean fatty liver. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, computed tomography; FFA, free fatty acids](JMD2-48-19-g001){#jmd212051-fig-0001}

After admission, the patient had a convulsion, which was immediately treated with diazepam (1 mg/kg). However, he did not regain consciousness and had no reaction to pain. Intravenous infusion including glucose was initiated after taking critical blood samples. Peramivir was also administered against the influenza A infection. Administration of carnitine and vitamin cocktail therapy including vitamin B1, B2, B12, C, and biotin was started, considering the possibility of mitochondrial dysfunction. At the second day of admission, his consciousness did not improve, and the severe metabolic acidosis lasted even after correction with sodium bicarbonate. Continuous electroencephalography monitoring revealed no high‐amplitude slow wave. On the third day, his symptoms improved dramatically. The patient reacted to stimulation and could open his eyes. He could sit by himself on day 4, and his consciousness became completely normal on day 5. The fatty liver and hepatomegaly were improved somewhat on day 11 (Figure [1](#jmd212051-fig-0001){ref-type="fig"}). A brain MRI performed on day 10 revealed no abnormality. The patient was discharged without any complication on day 14.

After discharge, he was managed with a normal diet and avoidance of long fasting periods. Around 3 months after the onset, he had enteritis. He overcame it without metabolic crisis with intravenous glucose administration at the local hospital. However, his liver was enlarged and his AST and ALT levels spiked again (Figure [1](#jmd212051-fig-0001){ref-type="fig"}). In 7 months after the onset, his AST and ALT levels finally normalized. In 13 months after the onset, the fatty liver had mostly disappeared, but mild hepatomegaly was still detected on CT. After the first episode of metabolic crisis, the patient experienced no further episodes of metabolic crisis even with minor illnesses. At the age of 6 years, he had grown and developed normally.

3. MATERIALS AND METHODS {#jmd212051-sec-0003}
========================

3.1. Biochemical analysis {#jmd212051-sec-0004}
-------------------------

Urinary organic acid levels were analyzed using gas chromatography mass spectrometry (GC/MS; QP‐2010 plus; Shimazu, Kyoto, Japan) at Shimane University, Japan, after solvent extraction and oxime‐trimethylsilyl derivatization of urine samples as previously described.[19](#jmd212051-bib-0019){ref-type="ref"}, [20](#jmd212051-bib-0020){ref-type="ref"} Urine metabolites were semi‐quantified by calculation of the relative peak area ratio (RPA, %) of each compound to margaric acid as the internal standard.[20](#jmd212051-bib-0020){ref-type="ref"}

The serum acylcarnitine level was analyzed using tandem mass spectrometry (MS/MS) (API‐3000; Applied Biosystems, Foster City, California) at Shimane University, Japan, after butyl‐derivatization of samples, as previously described.[21](#jmd212051-bib-0021){ref-type="ref"}, [22](#jmd212051-bib-0022){ref-type="ref"}

3.2. Mutation analysis {#jmd212051-sec-0005}
----------------------

Genomic DNA from the peripheral blood was extracted using standard phenol‐chloroform extraction methods. Mutation analysis was performed at the genomic level using polymerase chain reaction and direct sequencing, using a set of primer pairs that amplify fragments, including whole coding regions in all 10 exons and part of the 3′ flanking regions of *HMGCS2*. The primer sequences are presented in Supporting Information Table [S2](#jmd212051-supitem-0004){ref-type="supplementary-material"}. The genomic *HMGCS2* sequence was obtained from the NCBI Reference Sequence Database (accession No. NG_013348.1/NM_005518.3).

4. RESULTS {#jmd212051-sec-0006}
==========

Urinary organic acid obtained from the patient on admission was analyzed (Supporting Information Figure [S1](#jmd212051-supitem-0001){ref-type="supplementary-material"}). While the levels of dicarboxylic acids (glutarate, adipate, suberate, octenediate, 3‐OH‐adipate, 3‐OH‐suberate, and 3‐OH‐sebacate) were markedly increased, the excretion of ketone bodies (3‐OH‐butyrate and acetoacetate) was only mildly elevated. The increased excretion of glutarate was prominent (823.77%, normal range; \<4.00%). No other significant disease‐specific findings were detected at that time. 4HMP, which was retrospectively detected after the report of Pitt et al,[13](#jmd212051-bib-0013){ref-type="ref"} was not detected at the time of diagnosis.

Serum acylcarnitine analysis revealed slightly decreased free carnitine (C0) level (12.56 μM; normal range, 20‐60 μM) and increased acetylcarnitine level (C2; 92.1 μM; normal range, 4‐60 μM) (Supporting Information Table [S3](#jmd212051-supitem-0005){ref-type="supplementary-material"}). The levels of several kinds of acylcarnitine were slightly elevated, which were considered nonspecific reactions to the catabolic condition. After administration of carnitine, the C2 level was reduced but was still elevated (63.19 μM), as reported in the previous report.[9](#jmd212051-bib-0009){ref-type="ref"} These abnormal findings in the acute phase (during metabolic disruption) were no longer detected in the intermittent phase (between acute phases).

Fatty acid β‐oxidation defects were suggested from the clinical findings; however, the results of the biochemical analysis were not specific to fatty acid β‐oxidation defects. Therefore, we focused on the inborn errors of ketogenesis because the ratio of FFA to total ketone bodies (TKB) was markedly elevated (6.75; normal range for infants, 0.3‐2.5). The analysis of the *HMGCS2 gene* revealed two heterozygous mutations of c.130_131ins C (L44PfsX29) and c.1156_1157insC (L386PfsX73) (Supporting Information Figure [S2](#jmd212051-supitem-0002){ref-type="supplementary-material"}). Both were novel frameshift null mutations considered as pathogenic. The mutation of c.130_131insC (L44PfsX29) was inherited from the mother. The other mutation of c.1156_1157insC (L386PfsX73), which was also found in the elder sister, was suggested to be inherited from his father; however, analysis for his father could not be performed. These results confirmed the diagnosis of mHS deficiency.

5. DISCUSSION {#jmd212051-sec-0007}
=============

We report a case with mHS deficiency, which was the second case diagnosed in Japan (Fukao et al, unpublished data). The previous cases are summarized in Table [1](#jmd212051-tbl-0001){ref-type="table"}. Similar to other cases, our case presented with coma, hepatomegaly, fatty liver, and severe metabolic acidosis during acute infection and poor intake. While all previous cases presented with hypoglycemia except one case, which was investigated after infusion supply,[11](#jmd212051-bib-0011){ref-type="ref"} our case did not present with hypoglycemia. Our patient did not receive any glucose supply before blood examination on admission. The reason why hypoglycemia did not occur was unknown, but influenza virus infection might be related.

###### 

Patients with mHS deficiency

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case                                         Onset        Hypoglycemia          Fatty liver/hepatomegaly   Acylcarnitine profiles (in the acute phase)                            Organic acid profiles (in the acute phase)   HMGCS2 mutations       References
  -------------------------------------------- ------------ --------------------- -------------------------- ---------------------------------------------------------------------- -------------------------------------------- ---------------------- -------------------------------------------
  1                                            6 y          \+                    \+                         Normal carnitine\                                                      Normal                                       F174L/F174L            [7](#jmd212051-bib-0007){ref-type="ref"}\
                                                                                                             No more information                                                                                                                        [10](#jmd212051-bib-0010){ref-type="ref"}

  2                                            1 y 4 m      \+                    \+                         Normal                                                                 Dicarboxylic aciduria                        R424X/?                [12](#jmd212051-bib-0012){ref-type="ref"}

  3                                            11 m         \+                    \+                         Normal                                                                 Dicarboxylic aciduria                        G212R/R500H            [8](#jmd212051-bib-0008){ref-type="ref"}

  4                                            9 m          \+                    \+                         Normal                                                                 Dicarboxylic aciduria                        G212R/IVS5+1g\>a       [17](#jmd212051-bib-0017){ref-type="ref"}

  5                                            4.5 y        \+                    \+                         Normal                                                                 Dicarboxylic aciduria                        V54M/Y167C             [16](#jmd212051-bib-0016){ref-type="ref"}

  6[a](#jmd212051-note-0001){ref-type="fn"}    19 m         No data               \+                         Normal                                                                 Dicarboxylic aciduria                        V54M/Y167C             [16](#jmd212051-bib-0016){ref-type="ref"}

  7                                            7 m          \+                    \+                         Low C0\                                                                Dicarboxylic aciduria                        R188H/M307T            [9](#jmd212051-bib-0009){ref-type="ref"}
                                                                                                             Elevated C2 (dramatically increased after carnitine supplementation)                                                                       

  8[b](#jmd212051-note-0002){ref-type="fn"}    1 y          No data               \+                         Normal (nonacute)                                                      Normal (nonacute)                            R188H/M307T            [9](#jmd212051-bib-0009){ref-type="ref"}

  9                                            15 m         \+                    \+                         Normal                                                                 Dicarboxylic aciduria                        G388R/R424X            [15](#jmd212051-bib-0015){ref-type="ref"}

  10[c](#jmd212051-note-0003){ref-type="fn"}   8 m          \+                    \+                         No data                                                                No data                                      del ex1/del ex1        [13](#jmd212051-bib-0013){ref-type="ref"}

  11[c](#jmd212051-note-0003){ref-type="fn"}   9 m          \+                    \+                         No data                                                                No data                                      del ex1/del ex1        [13](#jmd212051-bib-0013){ref-type="ref"}

  12[c](#jmd212051-note-0003){ref-type="fn"}   6 m          \+                    \+                         No data                                                                4HMP\                                        del ex1/del ex1        [13](#jmd212051-bib-0013){ref-type="ref"}
                                                                                                                                                                                    Dicarboxylic aciduria                                               

  13[c](#jmd212051-note-0003){ref-type="fn"}   10 m         \+                    \+                         No data                                                                No data                                      del ex1/ del ex1       [13](#jmd212051-bib-0013){ref-type="ref"}

  14                                           3 y 1 m      \+                    −                          No data                                                                No data                                      L266S/I407T            [13](#jmd212051-bib-0013){ref-type="ref"}

  15                                           6 m          \+                    \+                         No data                                                                No data                                      G388R/G388R            [13](#jmd212051-bib-0013){ref-type="ref"}

  16[d](#jmd212051-note-0004){ref-type="fn"}   No episode   −                     −                          No data                                                                No data                                      G388R/G388R            [13](#jmd212051-bib-0013){ref-type="ref"}

  17                                           2 y 5 m      \+                    −                          No data                                                                No data                                      G169D/R505Q            [13](#jmd212051-bib-0013){ref-type="ref"}

  18                                           ?            \+                    No data                    No data                                                                No data                                      del ex1/del ex1        [13](#jmd212051-bib-0013){ref-type="ref"}

  19                                           ?            \+                    No data                    No data                                                                No data                                      G212R/V144fs           [13](#jmd212051-bib-0013){ref-type="ref"}

  20                                           ?            \+                    No data                    No data                                                                No data                                      Q283A/G232V            [13](#jmd212051-bib-0013){ref-type="ref"}

  21                                           ?            \+                    No data                    No data                                                                No data                                      W185R/Y503C            [13](#jmd212051-bib-0013){ref-type="ref"}

  22                                           ?            \+                    No data                    No data                                                                No data                                      S360P/S360P            [13](#jmd212051-bib-0013){ref-type="ref"}

  23                                           ?            \+                    No data                    No data                                                                No data                                      G168S/F174L            [13](#jmd212051-bib-0013){ref-type="ref"}

  24                                           8 m          -- (after infusion)   \+                         Low C0\                                                                Dicarboxylic aciduria\                       K137X/M381V            [11](#jmd212051-bib-0011){ref-type="ref"}
                                                                                                             Elevated C2 after carnitine supplementation                            Increased glutarate\                                                
                                                                                                                                                                                    Elevated 4HMP                                                       

  25                                           3 m          \+                    −                          Normal                                                                 Dicarboxylic aciduria                        R112W/?                [14](#jmd212051-bib-0014){ref-type="ref"}

  26                                           11 m         \+                    −                          Normal free carnitine\                                                 4HMP\                                        V144L/V144L            [14](#jmd212051-bib-0014){ref-type="ref"}
                                                                                                             Increased acylcarnitine                                                Dicarboxylic aciduria\                                              
                                                                                                                                                                                    Hydroxydicarboxylic aciduria                                        

  27                                           3 y          \+                    −                          No data                                                                Dicarboxylic aciduria                        R505Q/R505Q            [14](#jmd212051-bib-0014){ref-type="ref"}

  28                                           12 m         −                     \+                         Low C0\                                                                Dicarboxylic aciduria\                       L44PfsX29/L386PfsX73   This report
                                                                                                             Elevated C2                                                            Increased glutarate\                                                
                                                                                                                                                                                    4HMP                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sibling of \#5.

Sibling of \#7.

Family members, variable hepatomegaly was noted in several patients.

Sibling of \#15.

Our case showed marked hepatomegaly and very severe fatty liver at the onset. This may be associated with prolonged ketogenic stresses (7‐day febrile condition), rather than an acute episode of a few days illness in most cases. The fatty liver remained for \>3 months, and hepatomegaly was still found at 13 months after the first crisis (Figure [1](#jmd212051-fig-0001){ref-type="fig"}), on the contrary to the fatty acid oxidation defects. When he had enteritis 3 months after the first crisis, he did not present with hypoglycemia, but his AST and ALT values and liver size worsened again. That condition might be pre‐crisis.

The elevated FFA/TKB ratio (6.75; normal range, 0.3‐2.5) in this case likely suggested an inborn errors of ketogenesis as described previously.^18^ The FFA/TKB ratio had been high after recovering from the metabolic episode (Figure [1](#jmd212051-fig-0001){ref-type="fig"}). The values were higher in the intermittent phase than in the acute phase, maybe due to the increased ketogenesis from the branched chain amino acids in the acute phase.

The urine organic acid profile of our case was similar to those detected in previous cases. 4HMP was retrospectively detected in our case. As 4HMP has been reported to be a characteristic of mHS deficiency during hypoglycemic crisis,[13](#jmd212051-bib-0013){ref-type="ref"} it is a possible specific biochemical marker to diagnose the disease. In addition, our case showed increased excretion of glutarate, which was only reported in another case.[11](#jmd212051-bib-0011){ref-type="ref"} We also detected increased excretion of glutarate in the other cases of Japanese mHS deficiency (Fukao et al, unpublished data). As increased glutarate excretion is not evident in hypoketotic dicarboxylic aciduria in beta‐oxidation defects, this may also be a characteristic marker of mHS deficiency, although the etiology of increased glutarate is unknown.

Decreased free carnitine (C0) and increased acetylcarnitine (C2) levels in the acute phase were observed in our case, which was quite similar to one previous case reported by Aledo et al.[9](#jmd212051-bib-0009){ref-type="ref"} Conboy et al described that the C2/C0 ratio in the acute phase could be an additional biochemical signature of mHS deficiency.[11](#jmd212051-bib-0011){ref-type="ref"} The C2/C0 ratio in our case was also markedly elevated (7.33; 99th percentile, 1.83). As plenty of acetyl‐CoA is produced by beta‐oxidation but is not used for ketogenesis during ketogenic stresses such as fasting and febrile conditions in mHS deficiency, acetyl‐CoA should turn to acetylcarnitine in the liver to maintain the free CoA level. Hence, elevated C2 is expected in the catabolic condition in mHS‐deficient patients. Rapid increase in C2 level may result in C0 consumption. These findings could be the basis to suspect this disease. Furthermore, the fact that these abnormalities were only observed in the acute phase is also important.

Our patient had two frame‐shift mutations. To date, this is the only patient with two apparent null mutations beside homozygous deletion of exon 1.[13](#jmd212051-bib-0013){ref-type="ref"} His phenotype was not more severe than those of other cases with missense mutations. At the age of 1 year, after 14 hours of fasting from the last meal, he did not have hypoglycemia. The fasting tolerance in this patient is considered to be longer than 14 hours, while it was 12‐19 hours in other cases.[7](#jmd212051-bib-0007){ref-type="ref"}, [8](#jmd212051-bib-0008){ref-type="ref"}, [12](#jmd212051-bib-0012){ref-type="ref"}, [16](#jmd212051-bib-0016){ref-type="ref"} He had not experienced any metabolic crisis until 6 years of age. The clinical findings in our case suggest no apparent genotype‐phenotype correlations in this disorder.

The onset of previous cases was around the age of 0‐6 years (Table [1](#jmd212051-tbl-0001){ref-type="table"}). To date, no episode of metabolic decompensation has been reported after the age of 7 years. Despite the severity of metabolic compensation, most cases had good prognosis. However, some cases were reported to have retardation of cognitive and physical development or died from metabolic compensation.[11](#jmd212051-bib-0011){ref-type="ref"}, [18](#jmd212051-bib-0018){ref-type="ref"} Proper treatment during the onset of the sickness and in the acute crisis in patients with mHS deficiency is crucial. Therefore, the diagnosis at the first episode of metabolic compensation is important.

Here, we report some additional biochemical characteristics such as increased glutamate in urine and decreased free carnitine (C0) and increased acetylcarnitine (C2) levels in blood during acute crisis. Furthermore, we reported the elevated FFA/TKB ratio not only during crisis but also in the intermittent phase, which can be a diagnostic indicator. In addition, mHS deficiency cannot be excluded in a patient with severe metabolic acidosis with no or subtle ketosis and fatty liver, even without hypoglycemia.

ONE SENTENCE TAKE‐HOME MESSAGE {#jmd212051-sec-0008}
------------------------------

Mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA (HMG‐CoA) synthase deficiency (mHS deficiency) should be taken into consideration when a patient has severe metabolic acidosis and fatty liver with no or subtle ketosis, even without hypoglycemia.
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**Figure S1.** The profiles of urinary organic acid analysis using GC/MS. A, In the acute phase; B, In the intermittent phase

###### 

Click here for additional data file.
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**Figure S2.** Sequence analysis of the *HMGCS2* gene. Two heterozygous mutations of c.130_131ins C (L44PfsX29) and c.1156_1157insC (L386PfsX73) were identified
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**Table S1.** Laboratory examination on admission (before infusion glucose)
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**Table S2.** Amplification primer sets for *HMGCS2* exons
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**Table S3.** The acylcarnitine profiles of serum samples in the acute phase
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